PFE
USDPfizer Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$22.770
Kõrge
$23.100
Madal
$22.475
Maht
3.95M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
130.0B
Tööstusharu
Drug Manufacturers - General
Riik
United States
Kauplemisstatistika
Keskmine maht
50.85M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC)
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Guardant Health, Inc. (NASDAQ:GH), a
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.
Pfizer Declares Second-Quarter 2025 Dividend
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock,
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer's industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.